Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.68 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.58 |
| ▸ | ABL1 | P00519 | 4/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | WEE1 | P30291 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594853 | 0.91 | MAPK8 (0.59) | FGFR1MAPK8ABL1MAPK14EGFR | |
| SCHEMBL5113520 | 0.91 | MAPK8 (0.59) | FGFR1MAPK8ABL1MAPK14EGFR | |
| SCHEMBL14014657 | 0.91 | FGFR1 (0.70) | FGFR1MAPK8ABL1EGFRWEE1 | |
| SCHEMBL14014824 | 0.87 | MAPK14 (0.63) | FGFR1MAPK8ABL1MAPK14 | |
| SCHEMBL14014626 | 0.85 | WEE1 (0.68) | FGFR1MAPK8ABL1MAPK14EGFR | |
| SCHEMBL5120866 | 0.85 | MAPK14 (0.61) | FGFR1MAPK8ABL1MAPK14 | |
| SCHEMBL14014771 | 0.82 | MAPK8 (0.69) | FGFR1MAPK8ABL1MAPK14EGFR | |
| SCHEMBL29593396 | 0.81 | MAPK8 (0.74) | FGFR1MAPK8MAPK14EGFR | |
| SCHEMBL5107044 | 0.81 | MAPK8 (0.74) | FGFR1MAPK8MAPK14EGFR | |
| SCHEMBL5764908 | 0.81 | FGFR1 (1.00) | FGFR1ABL1MAPK14EGFRWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | FGFR1 1580/4885MAPK8 3523/4885ABL1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.